The iPLEDGE program is a computer-based risk management program designed to further the public health goal to eliminate fetal exposure to isotretinoin through a special restricted distribution program approved by the FDA. The program strives to ensure that:
No female patient starts isotretinoin therapy if pregnant
No female patient on isotretinoin therapy becomes pregnant
To learn more about this please click on iPledge Please note: the iPledge site is poorly designed -- you may have to click on (close window) to view is properly.